Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines

Current Opinion in Structural Biology

Volumn 6, Issue 2, 1996, Pages 176-182

  Lomonossoff, George P ^a   Johnson, John E ^b  

^a JOHN INNES CENTRE   (United Kingdom)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BACTERIOPHAGE; DRUG DESIGN; EXPRESSION VECTOR; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0029921999     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(96)80072-8     Document Type: Article

References (66)

1. Francis MJ: Enhanced immunogenicity of recombinant and synthetic peptide vaccines. In Vaccines. Edited by Gregoriadis G, Allison AC, Poste G. New York: Plenum Press; 1991:13-23.
2. Schaaper MM, Lankhof H, Pujik WC, Meloen RH: Manipulation of antipeptide immune response by varying the coupling of the peptide with the carrier protein. Mol Immunol 1989, 26:81-85.
3. Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228:1315-1317.
4. Scott JK, Craig L: Random peptide libraries. Curr Opin Biotechnol 1994, 5:40-48.
5. O'Neil KT, Hoess RH: Phage display: protein engineering by directed evolution. Curr Opin Struct Biol 1995, 5:443-449.
6. Makowski L: Phage display: structure, assembly and engineering of filamentous bacteriophage M13. Curr Opin Struct Biol 1994, 4:225-230.
7. De la Cruz VF, Lal AA, McCutchan TF: Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J Biol Chem 1988, 263:4318-4322.
8. Greenwood J, Willis AE, Perham RN: Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from Plasmodium falciparum circumsporozoite protein as antigens. J Mol Biol 1991, 220:821-827.
9. Ilyichev AA, Minenkova OO, Kishchenko GP, Tat'kov SI, Karpishev NN, Eroshkin AM, Ofitzerov VI, Akimenko ZA, Petrenko VA, Sandakhehiev LS: Inserting foreign peptides into the major coat protein of bacteriophage M13. FEBS Lett 1992, 301:322-324.
10. Makowski L: Structural constraints on the display of foreign peptides on filamentous bacteriophages. Gene 1993, 128:5-11.
11. Kishchenko G, Batliwala H, Makowski L: Structure of a foreign peptide displayed on the surface of bacteriophage M13. J Mol Biol 1994, 241:208-213. The structure of a mutant of M13 harbouring a five amino acid insertion near the N terminus of the major coat protein (pVIII) was determined to 7 Å resolution by fibre diffraction. Examination of the structure reveals that the inserted sequence is presented in an extended conformation between two α helices on the surface of the virions, mimicking the presentation of peptides in an MHC complex. This configuration may contribute to the high level of immunogenicity of peptides presented at the N terminus of gp8. This paper represents the first example of the determination of the structure of a peptide as presented on the surface of a heterologous particle.
12. Willis AE, Perham RN, Wraith D: Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage. Gene 1993, 128:79-83.
13. Veronese FDM, Willis AE, Boyer-Thompson C, Appella E, Perham RN: Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. J Mol Biol 1994, 243:167-172.
14. Mastico RA, Talbot SJ, Stockley PG: Multiple presentation of foreign peptides on the surface of an RNA-free bacteriophage capsid. J Gen Virol 1993, 74:541-548.
15. Valegård K, Liljas L, Fridborg K, Unge T: The three-dimensional structure of the bacterial virus MS2. Nature 1990, 345:36-41.
16. Stonehouse NJ, Valegård K, Golmohammadi R, Van den Worm S, Walton C, Stockley PG, Liljas L: Crystal structures of MS2 capsids with mutations in the subunit FG loop. J Mol Biol 1996, in press.
17. Maruyama IN, Maruyama HI, Brenner S: λ foo: a λ phage vector for the expression of foreign proteins. Proc Natl Acad Sci USA 1994, 91:8273-8277.
18. Sternberg N, Hoess RH: Display of peptides and proteins on the surface of bacteriophage λ. Proc Natl Acad Sci USA 1995, 92:1609-1613. Bacteriophage λ is used as a presentation system, with peptides being added to the N terminus of the 11 kDa D protein present in 420 copies on the T=7 lattice on the virus head. To produce large protein D fusion display libraries without having to clone many fragments of DNA directly into λ DNA, the authors use a site-specific recombination system in vivo to incorporate plasmids encoding D fusions into the phage genome. Assembly of the bacteriophage occurs normally and the peptide is accessible on the virus surface. The system will probably be most useful for the display of sequences obtained from cDNA libraries.
19. Burns NR, Saibil HR, White NS, Pardon JF, Timmins PA, Richardson SMH, Richards BM, Adams SE, Kingsman SM, Kingsman AJ: Symmetry, flexibility and permeability in the structure of yeast retrotransposon virus-like particles. EMBO J 1992, 11:1155-1164.
20. Adams SE, Dawson KM, Gull K, Kingsman SM, Kingsman AJ: The expression of hybrid HIV:Ty virus-like particles in yeast Nature 1987, 329:68-70.
21. Brookman JL, Stott AJ, Cheeseman PJ, Burns NR, Adams SE, Kingsman AJ, Gull K: An immunological analysis of Ty1 virus-like particle structure. Virology 1995, 207:59-67.
22. Brookman JL, Stott AJ, Cheeseman PJ, Adamson CS, Holmes D, Cole J, Burns NR: Analysis of TYA protein regions necessary for formation of the Ty1 virus-like particle structure. Virology 1995, 212:69-76. Deletion mutagenesis was used to determine which regions of the TYA protein are necessary for the formation of Ty virus-like particles. The results show that regions from both the N and C terminus as well as certain internal regions of the protein can be deleted without abolishing particle assembly. The findings will be useful in the further development of Ty particles as antigen-presentation systems.
23. Valenzuela P, Coit D, Medina-Selby A, Kuo C, Van Nest G, Burke RL, Bull P, Urdea MS, Graves RV: Antigen engineering in yeast: synthesis and assembly of hybrid hepatitis B surface antigen-herpes simplex 1 gD particles. Biotechnology 1985, 3:323-326.
24. Delpeyroux F, Chenciner N, Lim A, Malpièce Y, Blondel B, Crainic R, Van der Werf S, Streeck RE. A poliovirus neutralisation epitope expressed on hybrid hepatitis B surface antigen particles. Science 1986, 233:472-475.
25. Rutgers T, Gordon D, Gathoye AM, Hollingdale M, Hockmeyer W, Rosenberg M, De Wilde M: Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. Biotechnology 1988, 6:1065-1070.
26. Moelans IIMD, Cohen J, Marchand M, Molitor C, De Wilde P, Van Pelt JF, Hollingdale MR, Roeffen WFG, Eling WMC, Atkinson CT et al.: Induction of Plasmodium falciparum sporozoite-neutralising antibodies upon vaccination with recombinant pfs16 Vaccinia virus and/or recombinant pfs16 protein produced in yeast. Mol Biochem Parasitol 1995, 72:179-192.
27. Schlienger K, Mancini, Rivière Y, Dormont D, Tiollais P, Michel M-L: Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. J Virol 1992, 66:2570-2576.
28. Sonveaux N, Ruysschaert JM, Brasseur R: Proposition of a 3-dimensional representation of the constitutive protein of the hepatitis B surface antigen particles. J Protein Chem 1995, 14:477-486.
29. Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, Highfield PE, Rowlands DJ, Brown F: Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 1987, 330:381-384.
30. Brown AL, Francis MJ, Hastings GZ, Parry NR, Barnett PV, Rowlands DJ, Clarke BE: Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted. Vaccine 1991, 9:595-601.
31. Schodel F, Moriarty AM, Peterson DJ, Zheng J, Hughes JL, Will H, Leturcq DJ, McGee JS, Milich DR: The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol 1992, 66:106-114.
32. Yon J, Rud E, Corcoron T, Kent K, Rowlands D, Clarke B. Stimulation of specific immune-responses to simian immunodeficiency virus using chimaeric hepatitis B core antigen particles. J Gen Virol 1992, 73:2569-2575.
33. Von Brunn A, Brand M, Reichhuber C, Moryswortmann C, Demhardt F: Principal neutralising domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine 1993, 11:817-824.
34. Tindle RW, Herd K, Londoo P, Fernando GJP, Chatfield SN, Malcolm K, Dougan G: Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice. Virology 1994, 200:547-557.
35. Boulter NR, Glass EJ, Knight PA, Bellsakyi L, Brown CGD, Hall R: Theileria annulata sporozoite antigen fused to hepatitis B core antigen used in a vaccination trial. Vaccine 1995, 13:1152-1160. A 108 amino acid sequence from a sporozoite surface antigen of the tick-borne protozoan parasite Theileria annulata was inserted into the e1 loop of HBcAg. The insertion of such a large sequence did not prevent the formation of particles when the chimaeric protein was expressed in E. coli. The particles were shown to be able to partially protect cattle against infection by T. annulata.
36. French TJ, Roy P: Synthesis of bluetongue virus core-like particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J Virol 1990, 64:1530-1536.
37. 2 epitope on bluetongue virus core-like particles. Virology 1992, 190:840-844.
38. Tanaka S, Mikhailov M, Roy P: Synthesis of bluetongue virus chimaeric VP3 molecules and their interactions with VP7 protein to assemble into virus core-like particles. Virology 1995, 214:593-601.
39. Grimes J, Basak A, Roy P, Stuart D: The crystal structure of bluetongue virus VP7: implications for virus assembly. Nature 1995, 373:167-170.
40. Chapman MS, Rossmann MG: Structure, sequence and function correlations among parvoviruses. Virology 1993, 194:491-508.
41. Brown CS, Welling-Wester S, Feijlbrief M, Van Lent JWM, Spaan WJM: Chimeric parvovirus B19 capsids for the presentation of foreign epitopes. Virology 1994, 198:477-488. Chimaeric human parvovirus VP2 subunits containing epitopes from herpes simplex virus and mouse hepatitis virus were constructed and expressed in insect cells. The subunits spontaneously assembled into particles when the peptides were fused either to the N terminus of VP2 or in a loop predicted to be exposed on the basis of the 3D structure of canine parvovirus. Peptides inserted into the loop appeared to be more exposed than those at the N terminus, demonstrating the value of knowledge of the 3D structure of the carrier.
42. Sedlik C, Sarraseca J, Rueda P, Leclerc C, Casal I: Immunogenicity of poliovirus B and T cell epitopes presented by hybrid porcine parvovirus particles. J Gen Virol 1995, 76:2361-2368.
43. Miyamura K, Kajigaya S, Momoeda M, Smith-Gill SJ, Young NS: Parvovirus particles as platforms for protein presentation. Proc Natl Acad Sci USA 1994, 91:8507-8511.
44. Haynes JR, Cunningham J, Von Seefried, Lennick M, Garvin RT, Shen S-H: Development of a genetically engineered, candidate polio vaccine employing the self-assembling properties of the tobacco mosaic virus coat protein. Biotechnology 1986, 4:637-641.
45. Hwang D-J, Roberts IM, Wilson TMA: Expression of tobacco mosaic virus coat protein and assembly of pseudovirus particles in Escherichia coli. Proc Natl Acad Sci USA 1994, 91:9067-9071.
46. Jagadish MN, Hamilton RC, Fernandez CS, Schoofs P, Davern KM, Kalnins H, Ward CW, Nisbet IT: High level production of hybrid potyvirus-like particles carrying repetitive copies of foreign antigens in Escherichia coli. Biotechnology 1993, 11:1166-1170.
47. Evans DJ, Almond JW: Design, construction and characterisation of poliovirus antigen chimaeras. Methods Enzymol 1991, 203:386-400.
48. Rose C, Andrews W, Ferguson M, McKeating J, Almond J, Evans D: The construction and characterization of poliovirus antigen chimaeras presenting defined regions of the human T lymphocyte marker CD4. J Gen Virol 1994, 75:969-977.
49. Yeates TO, Jacobson DH, Martin A, Wychowski C, Girard M, Filman DJ, Hogel JM: Three-dimensional structure of a mouse-adapted type 2/type 1 poliovirus chimera. EMBO J 1991, 10:2331-2341.
50. Arnold GF, Resnick DA, Li Y, Zhang A, Smith AD, Geisler SC, Jacobo-Molina A, Lee W-M, Webster RG, Arnold E: Design and construction of rhinovirus chimeras incorporating immunogens from polio, influenza and human immunodeficiency viruses. Virology 1994, 198:703-708.
51. Smith AD, Resnick DA, Zhang A, Geisler SC, Arnold E, Arnold GF: Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimaeras displaying human immunodeficiency virus type 1 V3 loop sequences. J Virol 1994, 68:575-579. A novel strategy was developed to optimize the linkage of inserted polypeptides to residues of the VP2 subunit of HRV14. Using random mutagenesis of two residues on either side of the insert, a selection of linkers was produced that optimized replication of the chimaeras. The random systematic mutagenesis methodology described in this paper should be generally useful for the rapid insertion of foreign sequences into viral coat proteins.
52. Resnick DA, Smith AD, Zhang A, Geisler SC, Arnold E, Arnold GF: Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis. AIDS Res Hum Retroviruses 1994, 10(suppl 2):47-52.
53. Resnick DA, Smith AD, Geisler SC, Zhang A, Arnold E, Arnold GF: Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralising responses against HIV-1. J Virol 1995, 69:2406-2411.
54. London SD, Schmaljohn AL, Dalrymple JM, Rice CM: Infectious enveloped RNA virus antigenic chimeras. Proc Natl Acad Sci USA 1992, 89:207-211.
55. King AMQ, Lomonossoff GP, Ryan MD: Picornaviruses and their relatives in the plant kingdom. Semin Virol 1991, 2:11-17.
56. Lomonossoff GP, Johnson JE: Eukaryotic viral expression systems for polypeptides. Semin Virol 1995, 6:257-267. A detailed discussion of structure-based insertional mutagenesis is presented with particular reference to the plant virus CPMV. The discussion should be helpful in the selection of potential sites of insertion for a variety of different systems.
57. Usha R, Rohll JB, Spall VE, Shanks M, Maule AJ, Johnson JE, Lomonossoff GP: Expression of an animal virus antigenic site on the surface of a plant virus particle. Virology 1993, 197:366-374.
58. Porta C, Spall VE, Loveland J, Johnson JE, Barker PJ, Lomonossoff GP: Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. Virology 1994, 202:949-955. The icosahedral plant virus CPMV was used to express epitopes from several animal viruses as insertions into the capsid S protein. In two out of three cases, the modified particles grow as well as wild-type CPMV. Particles expressing an epitope from HRV14 are shown to be able to elicit the production of anti-HRV14 antibodies when injected into rabbits. This is the first example of the use of an infectious plant virus as an epitope-presentation system.
59. McLain L, Porta C, Lomonossoff GP, Durrani Z, Dimmock NJ: Human immunodeficiency virus type 1 neutralizing antibodies raised to a gp41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retroviruses 1995, 11:327-334.
60. McLain L, Durrani Z, Wisniewski LA, Porta C, Lomonossoff GP, Dimmock NJ: Stimulation of neutralising antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide peptide of gp41 expressed on the surface of a plant virus. Vaccine 1996, in press.
61. Porta C, Spall VE, Lin T, Johnson JE, Lomonossoff, GP: The development of cowpea mosaic virus as a source of novel vaccines. Intervirology 1996, in press.
62. Takamatsu N, Watanabe Y, Yanagi H, Meshi T, Shiba T, Okada Y: Production of enkephalin in tobacco protoplasts using tobacco mosaic virus RNA vector. FEBS Lett 1990, 269:73-76.
63. Hamamoto H, Sugiyama Y, Nakagawa N, Hashida E, Matsunaga Y, Takemoto S, Watanabe Y, Okada Y: A new tobacco mosaic virus vector and its use for the systemic production of angiotensin-I-converting enzyme inhibitor in transgenic tobacco and tomato. Biotechnology 1993, 11:930-932.
64. Turpen TH, Reinl SJ, Charoenvit Y, Hoffman SL, Fallarme V, Grill LK: Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology 1995, 13:53-57. Epitopes from the malarial parasite were expressed on the surface of the helical plant virus TMV. Two sites for insertion were identified: the C terminus of the viral coat protein and an exposed loop. The resulting chimaeras grew well and the particles had the antigenic properties of the insert. In view of the ease of propagation and stability of TMV, this approach could prove an effective way of producing novel vaccines.
65. Fitchen J, Beachy RN, Hein MB: Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Vaccine 1995, 13:1051-1057.
66. Benito A, Mateu MG, Villaverde A: Improved mimicry of a foot and mouth disease virus antigenic site by a viral peptide displayed on β-galactosidase surface. Biotechnology 1995, 13:801-804. The antigenicity of several recombinant E. coli β-galactosidases displaying the immunodominant epitope from FMDV in different sites on the enzyme surface was studied. For each site, the inserted peptide showed a different specificity with a set of anti-FMDV monoclonal antibodies directed against the epitope. The results indicate that the precise way a sequence is presented on the surface of a macromolecule can dramatically influence its immunological properties.